NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.
We help you plan and evaluate strategies to achieve success in U.S. and global markets.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Insights KPI is the only digital platform that measures and showcases your market access success across every brand in your portfolio – helping you deliver and communicate the commercial impact of your portfolio.
From NAVLIN by EVERSANA, the most trusted name in price & market access.
Stay ahead in a rapidly changing policy environment with the MFN Tracker from NAVLIN Insights. This subscription-based resource delivers weekly updates on market trends, launch strategies, pricing shifts, and payer reactions—giving you the clarity and confidence to make informed decisions.
Join the growing number of executives leveraging MFN Tracker to navigate uncertainty and drive results. Subscribe now to unlock actionable market intelligence and stay ahead of the curve.
From continuous discovery to submission and post-award tracking — NAVLIN by EVERSANA industrializes every step of the tender lifecycle with AI, delivering faster decisions, stronger margins, and scalable compliance across 70+ markets.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Insights KPI is the only digital platform that measures and showcases your market access success across every brand in your portfolio – helping you deliver and communicate the commercial impact of your portfolio.
From NAVLIN by EVERSANA, the most trusted name in price & market access.
Stay ahead in a rapidly changing policy environment with the MFN Tracker from NAVLIN Insights. This subscription-based resource delivers weekly updates on market trends, launch strategies, pricing shifts, and payer reactions—giving you the clarity and confidence to make informed decisions.
Join the growing number of executives leveraging MFN Tracker to navigate uncertainty and drive results. Subscribe now to unlock actionable market intelligence and stay ahead of the curve.
From continuous discovery to submission and post-award tracking — NAVLIN by EVERSANA industrializes every step of the tender lifecycle with AI, delivering faster decisions, stronger margins, and scalable compliance across 70+ markets.
650+
+99%
<24
4,000+
24x7
99.5%
Last week, NAVLIN Daily brought you key market access developments from across the globe In the U.S., nine major PBMs moved to integrate TrumpRx cash prices into benefit tools, while a new BLS report found that prescription drug prices fell 3.1% from July 2025 to July 2026, their sharpest annual decline in more than 60 years In Japan, a health ministry-funded research group broadly agreed on its technical review of the CEA system
Following China's latest VBP round in July, PhIRDA reports that the system now favors big players more heavily. Hospitals can specify brand preferences, and revival bids can benefit original brands and leading genericsAt the same time, some manufacturers continue to cut prices by 80% to stay competitive, disrupting markets and straining anti-involution effortsIncreasingly complicated rules, with anchors and weight systems, aim to balance needs but risk overshadowing core VBP goals, leaving policymakers with lingering hurdles
Sales of generic GLP-1 injectable drugs in India reached Rs 460 million ($4.81 million, at the time of publishing) by July 2026, with volume rising to 192,000 units, according to India Ratings and Research (Ind-Ra)The segment has expanded since generic versions became available following the expiry of semaglutide’s patent in March, with lower-priced alternatives supporting increased uptake These products are priced 50% to 75% below branded products such as Ozempic (semaglutide) and Wegovy (semaglutide)
Germany's Federal Joint Committee (G-BA) could not consider the final Joint Clinical Assessment (JCA) report for Ojemda because it had not been published when the German benefit assessment began, although the JCA dossier formed part of the evidence reviewedG-BA rejected Ipsen's matching-adjusted indirect comparison (MAIC) from the JCA dossier for the German benefit assessment and instead based its assessment primarily on the single-arm FIREFLY-1 study, using a newer three-year data cutAs an orphan drug, Ojemda underwent Germany's abbreviated assessment procedure; if annual sales exceed EUR 30 million, it will become subject to a standard benefit assessment
A Japanese health ministry-funded research group has broadly approved its draft conclusions on technical reforms to the country’s cost-effectiveness assessment (CEA) systemThe group called for greater opportunities for manufacturers to attend CEA organization meetings and better use of an existing mechanism for considering important new evidenceA final report is expected to be submitted to the Central Social Insurance Medical Council (Chuikyo) in September, although industry representatives have called for further technical discussions
A tissue-engineered skin product for burns has entered the European Union’s joint clinical assessment (JCA) processThe product is the first tissue-engineered therapy to enter JCA and the fourth non-oncology advanced therapy medicinal product (ATMP)HAS will lead the JCA, with RIZIV-INAMI serving as co-assessor. This is the fourth JCA involving the French national HTA agency and the third involving the Belgian organization
Last week, NAVLIN Daily brought you key market access developments from across the globe In the U.S., we saw scrutiny of TrumpRx’s early impact and a new bill targeting foreign drug pricing policies Across the pond, NICE published an AI delivery plan, and France began to think about this year’s PLFSS, with CNAM suggesting €1.3 billion in savings from healthcare products
A new Interpharma survey found that drugmakers declined to seek Swiss reimbursement for seven of 22 innovative medicines and withheld three from Swissmedic approval between January 2025 and June 2026, citing U.S. MFN policyThe association said the 18-month average of 15 reimbursement submissions compares with 24 medicines submitted annually between 2019 and 2025, indicating reduced Swiss access to new therapiesInterpharma warned that proposed Health Insurance Ordinance revisions, which focus on cost containment, could further delay launches, increase price pressure and reduce clinical trials
Henan province has led an inter-provincial drug procurement round with 34 drug varieties up for bidding. A total of 130 pharmaceutical firms were selected across 269 drug specificationsThe variety groups were split into competitive high-quality drugs (Group A) and lower-priced options (Group B)The procurement batch involved 32 provinces, municipalities, and regions across China, including heavyweights like Beijing, Shanghai, and Guangdong
The overall impact of TrumpRx appears limited based on the first few months of the program, according to new reporting from POLITICOAccording to a 10-Q filed by GoodRx and reviewed by POLITICO, the discount drug retailer has not noticed a material impact on its business from the programEarly demand has been concentrated in GLP-1 therapies, though GoodRx said the program’s longer-term impact remains uncertain as MFN pricing and direct-to-consumer drug access expand
